Characterization of platelet aggregation disorders
CA 2096230 C · Owner: Ginsberg, Mark H. · Inventors: Ginsberg, Mark H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation ligand, binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombastenia is characterized as having a ligand binding defect. In another embodiment a patient , with myelofibrosis is identified as having an activation defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described which comprise antibodies suitable for characterizing the above defects.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 15, 1991 and granted May 27, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 15, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 15, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.